Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Clinical trial NCT02041429 · COMPLETED
Trial details
- NCT number
- NCT02041429
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-01
- Primary completion
- 2016-05-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.